Ebselen has dehydroascorbate reductase and thioltransferase-like activities

Comprehensive modeling of the antioxidant mechanism of ebselen

Three possible catalytic cycles for ebselen have been comprehensively modeled by theoretical calculations using density functional theory (DFT) at a mixed basis set level; the 6-31G(d) basis set for hydrocarbon fragments and the 6-31[Formula: see text]G(d,p) basis set for other atoms. The 2[Formula: see text] cycle is the main pathway in the glutathione peroxidase (GPx) cycle (cycle A), and IM3[Formula: see text]TS3 is the rate controlling process. The 1[Formula: see text]1 cycle is the main pathway for the oxidation cycle (cycle B), and the rate controlling step is the [Formula: see text] step. Ebselen reacts with the selenol 3 to form the diselenide 9, and this is the rate controlling step for cycle C. The extremely high energy barrier for the IM9[Formula: see text]TS9 process indicates that cycle C is unlikely to occur in vivo. Although cycle B is favored based on the energy analysis, with a maximum energy barrier of only 26.68[Formula: see text]kcal/mol at the mixed basis set level, it is generally unlikely to have very high concentrations of peroxides present in vivo. The results indicate that in order to improve the antioxidant activity of ebselen, it would be necessary to suitably modify the molecular structure of ebselen to reduce the energy barrier of the IM3[Formula: see text]TS3 process.

Diphenyl diselenide in its selenol form has dehydroascorbate reductase and glutathione S-transferase-like activity dependent on the glutathione content

Objectives

The antioxidant action of diphenyl diselenide ((PhSe)2) is attributed to the mechanism by which (PhSe)2 has pharmacological activity. Although (PhSe)2 has glutathione peroxidase mimetic activity, the exact mechanism involved in its antioxidant effect has not yet been completely elucidated. In the present study, mechanisms involved in the antioxidant property of (PhSe)2 (1–50 µm) were investigated.

Methods

Dehydroascorbate (DHA) reductase- and glutathione S-transferase (GST)-like activity, 2,2′-diphenyl-1-picrylhydrazyl (DPPH) and 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) radical-scavenging activity and the protection against the oxidation of Fe2+ were evaluated.

Key findings

(PhSe)2 at concentrations equal to, or greater than, 5 µm showed DHA reductase- and GST-like activity. (PhSe)2 was not a scavenger of DPPH or ABTS radicals and did not protect against the oxidation of Fe2+.

Conclusions

These results clearly indicated that DHA reductase- and GST-like activity are the mechanisms involved in the antioxidant effect of (PhSe)2.

Redox modulation at the peripheral site alters nociceptive transmission in vivo

1. The aim of the present study was to investigate the role of redox modulation during the peripheral nociceptive transmission in vivo. The nociceptive response was evaluated by the amount of time that mice spent licking the footpad injected with glutamate (20 micromol/paw). Thiol groups in footpad tissue were quantified using a colourimetric reaction with 5,5'-dithio-bis-2-nitrobenzoic acid (DTNB). 2. When coadministered with glutamate, the thiol alkylating agent iodoacetate (200 nmol/paw) caused significant antinociception in footpad tissue, in parallel with a decrease in free thiol groups. Treatment with the reducing agent dithiothreitol (200 nmol/paw) 5 min before glutamate and iodoacetate prevented the antinociception and thiol loss caused by iodoacetate. Injection of 100 nmol/paw ebselen (2-phenyl-1,2-benzisoselenazol-3[2H]-one), an in vitro redox modulator of the N-methyl-d-aspartate (NMDA) receptor, also prevented iodoacetate-induced antinociception. However, ebselen did not prevent thiol loss in the footpad. Dithiothreitol and ebselen had a synergic nociceptive effect with glutamate. 3. Alone, ebselen (100 nmol/paw) exhibited a pronociceptive effect. The nociception induced by ebselen was blocked by glutathione depletion induced by buthionine-sulphoximine (BSO; 2.5 micromol/paw). In addition, ebselen-induced nociception was prevented by 75 +/- 2% following injection of 5 nmol/paw MK-801 (an NMDA receptor antagonist). The nitric oxide synthase inhibitor N(G)-nitro-l-arginine (250 nmol/paw) had no effect on the nociception produced by ebselen. 4. In conclusion, the present paper reports on the effect of redox modulation on the glutamatergic system during peripheral nociceptive transmission in vivo. Antinociception was directly correlated with the availability of thiol groups, whereas the pronociceptive response of the reducing agents likely occurs via positive modulation of the NMDA receptor.

Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase

Previous studies indicate that noise induced hearing loss (NIHL) involves a decrease in glutathione peroxidase (GPx) activity and a subsequent loss of outer hair cells (OHC). However, the cellular localization of this GPx decrease and the link to OHC loss are still poorly understood. In this report, we examined the cellular localization of GPx (GPx1, GPx 3 and GPx 4) in F-344 rat before and after noise exposure and after oral treatment with ebselen, a small molecule mimic of GPx activity. Results indicate that GPx1 is the major isoform within the cochlea and is highly expressed in cells of the organ of Corti, spiral ganglia, stria vascularis, and spiral ligament. Within 5h of noise exposure (4h at 113 dB, 4-16 kHz), significant OHC loss was already apparent in regions coincident with the 8-16 kHz region of the cochlea. In addition, the stria vascularis exhibited significant edema or swelling and a decrease in GPx1 immunoreactivity or fluorescent intensity. Treatment with ebselen (4 mg/kg p.o.) before and immediately after noise exposure reduced both OHC loss and the swelling of the stria vascularis typically observed within 5h post-noise exposure. Interestingly, GPx1 levels increased in the stria vascularis after noise and ebselen treatment vs noise and vehicle-only treatment, and exceeded baseline no noise control levels. These data indicate that ebselen acts to prevent the acute loss of OHCs and reduces the acute swelling of the stria vascularis by two potential mechanisms: one, as a ROS/RNS scavenger through its intrinsic GPx activity, and two, as a stimulator of GPx1 expression or activity. This latter mechanism may be due to the preservation of endogenous GPx1 from ROS/RNS induced degradation and/or the stimulation of GPx1 expression or activity.

Compounds for the prevention and treatment of noise-induced hearing loss

Noise-induced hearing loss (NIHL) is the leading occupational disease and a major contributor to the development of age-related hearing loss. The pharmacological prevention and treatment of NIHL has been under preclinical investigation for the past 20 years. Promising treatments have now been identified and entered into clinical development. Within the next five years, safe and effective drugs could be approved as the first generation of otoprotectants. This review covers strategies that are under investigation for NIHL. Drugs that effectively prevent and treat NIHL will have a significant impact on medical costs, disability compensation and several issues affecting the quality of life.

Ebselen is a dehydroascorbate reductase mimic, facilitating the recycling of ascorbate via mammalian thioredoxin systems

Ebselen is a selanazal drug recently revealed as a highly efficient peroxiredoxin mimic catalyzing the hydroperoxide reduction by the mammalian thioredoxin system [thioredoxin (Trx), thioredoxin reductase (TrxR), and NADPH]. The mammalian Trx system is a dehydroascorbic acid reductase recycling ascorbic acid essential for cell functions. Here we report that ebselen strongly facilitated the recycling of ascorbic acid by the TrxR both with and without Trx present. Reduction of dehydroascorbic acid by TrxR has a pH optimum of 6.4, and only approximately 55% of this activity at a physiological pH of 7.4. Ebselen at 6 microM enhances this reaction three-fold and with the same pH optimum of 6.4. The mechanism of the ebselen effect is suggested to involve reduction of dehydroascorbic acid by the ebselen selenol, a highly efficient two-electron reductant. Thus, ebselen acts as an antioxidant to lower the peroxide tone inside cells and to facilitate the recycling of dehydroascorbic acid to ascorbic acid, so as to increase the radical scavenging capacity of ascorbic acid directly or indirectly via vitamin E. The high ascorbic acid recycling efficiency of ebselen at pH 6.4 may play a major role in oxidatively stressed cells, where cytosol acidosis may trigger various responses, including apoptosis.